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Plasma glial fibrillary acidic protein is elevated in
cognitively normal older adults at risk of
Alzheimer’s disease
Pratishtha Chatterjee 1,2, Steve Pedrini2, Erik Stoops3, Kathryn Goozee 1,2,4,5,6,7, Victor L. Villemagne8, Prita R. Asih1,
Inge M. W. Verberk 9, Preeti Dave1,5, Kevin Taddei2,10, Hamid R. Sohrabi1,2,10,11, Henrik Zetterberg 12,13,14,15,
Kaj Blennow 12,13, Charlotte E. Teunissen9, Hugo M. Vanderstichele16 and Ralph N. Martins 1,2,4,6,7,10
Abstract
Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been
associated with Alzheimer’s disease (AD). However, plasma GFAP has not been investigated in cognitively normal older
adults at risk of AD, based on brain amyloid-β (Aβ) load. Cross-sectional analyses were carried out for plasma GFAP and
plasma Aβ1–42/Aβ1–40 ratio, a blood-based marker associated with brain Aβ load, in participants (65–90 years)
categorised into low (Aβ−, n= 63) and high (Aβ+, n= 33) brain Aβ load groups via Aβ positron emission
tomography. Plasma GFAP, Aβ1–42, and Aβ1–40 were measured using the Single molecule array (Simoa) platform.
Plasma GFAP levels were significantly higher (p < 0.00001), and plasma Aβ1–42/Aβ1–40 ratios were significantly lower
(p < 0.005), in Aβ+ participants compared to Aβ− participants, adjusted for covariates age, sex, and apolipoprotein E-
ε4 carriage. A receiver operating characteristic curve based on a logistic regression of the same covariates, the base
model, distinguished Aβ+ from Aβ− (area under the curve, AUC= 0.78), but was outperformed when plasma GFAP
was added to the base model (AUC= 0.91) and further improved with plasma Aβ1–42/Aβ1–40 ratio (AUC= 0.92). The
current findings demonstrate that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD.
These observations suggest that astrocytic damage or activation begins from the pre-symptomatic stage of AD and is
associated with brain Aβ load. Observations from the present study highlight the potential of plasma GFAP to
contribute to a diagnostic blood biomarker panel (along with plasma Aβ1–42/Aβ1–40 ratios) for cognitively normal
older adults at risk of AD.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia and it is estimated that globally over 50 million
people are living with AD or other forms of dementia1.
Currently, there is no cure or effective treatment for AD
despite all scientific efforts and therefore, more recent
clinical trials are focussing on prevention programmes for
AD, thereby requiring the identification of populations at
risk of AD.
Extracellular amyloid-β (Aβ) plaques and intracellular
neurofibrillary tangles comprising tau are the major
neuropathological hallmarks of AD and while a post-
mortem examination identifying these hallmarks is relied
upon for a confirmative diagnosis, Aβ and tau neuro-
pathology associated with AD can be identified in vivo via
positron emission tomography (PET) and cerebrospinal
fluid (CSF) analysis 15–20 years prior to symptom onset2.
However, the cost of PET imaging, the throughput of
imaging in general and the invasiveness of lumbar punc-
ture, required for CSF sample collection, restrict the
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implementation of these markers in standard clinical
practice and as screening tools in clinical trials. In con-
trast, the cost effective and less invasive nature of blood-
based biomarkers could serve as attractive surrogate
markers for initial clinical diagnostic testing and screening
for clinical trials.
Glial fibrillary acidic protein (GFAP) is an astrocytic
cytoskeletal protein that serves as a marker of abnormal
activation and proliferation of astrocytes due to neuronal
damage, also known as astrogliosis3. Astrogliosis has also
been observed around Aβ plaques from the prodromal
stages of AD, such as the mild cognitive impairment
stage4, and GFAP expression has been reported to cor-
relate with Aβ plaque density in AD brain tissue5. In
addition, higher GFAP levels have been reported in CSF
samples from individuals with AD and other dementias,
compared to healthy controls6.
Interestingly, relatively recent studies have also reported
higher GFAP levels in the blood in early and late-onset
AD7–9. GFAP levels in the blood were also observed to
inversely correlate with cognition8 and positively correlate
with the extent of white matter injury7. The current study
investigated whether elevated GFAP levels in the blood
precede the onset of the clinical symptoms of AD in
cognitively normal older adults at risk of AD.
Given that the onset of abnormal brain Aβ load build-
up assessed using PET begins as early as two decades
prior to the clinical manifestation of AD, and is a pro-
dromal feature and biomarker of AD2,10, plasma GFAP
levels were compared between cognitively normal older
adults with low brain Aβ load (Aβ−) and cognitively
normal older adults at risk of AD, due to high brain Aβ
load, (Aβ+)11. Our hypothesis was that plasma GFAP
levels will be higher in the Aβ+ group compared to the
Aβ− group.
The current study also evaluated the potential of plasma
GFAP in differentiating between Aβ+ and Aβ− indivi-
duals. In addition, given that the association between
plasma Aβ42/Aβ40 ratios and brain Aβ load has been
extensively reported12–15, this study also evaluated the
combined potential of plasma GFAP and plasma Aβ1–42/
Aβ1–40 ratios in discriminating between Aβ+ and Aβ−
individuals. Furthermore, associations of plasma GFAP
with the AD risk factors, cognitive performance, and
neurodegeneration marker, neurofilament light (NF-L),
were also assessed in the present study.
Materials and methods
Participants and cognitive assessments
Participants in the current study were from the Kerr
Anglican Retirement Village Initiative in Aging Health
(KARVIAH) cohort16. All participants from the KARVIAH
cohort met the inclusion and exclusion criteria, wherein the
inclusion criteria comprised an age range of 65–90 years,
good general health, no known significant cerebral vascular
disease, fluent in English, adequate/corrected vision and
hearing to enable testing, and no dementia or other
pathological cognitive impairment, as primarily screened by
a Montreal Cognitive Assessment (MoCA) score ≥26.
MoCA scores lying between 18 and 25 were assessed on a
case by case basis by the study neuropsychologist following
stratification of scores, using age and education-adjusted
norms17. The exclusion criteria comprised, previous diag-
nosis of dementia18, presence of acute functional psychiatric
disorder (including lifetime history of schizophrenia or
bipolar disorder), history of stroke, severe or extremely
severe depression (based on the Depression Anxiety Stress
Scales; DASS), and uncontrolled hypertension (systolic
BP > 170mm Hg or diastolic BP > 100mm Hg). From the
volunteers who met the inclusion and exclusion criteria
(n= 134), 105 participants underwent neuroimaging, neu-
ropsychometric evaluation, and blood collection since the
remaining participants declined undergoing neuroimaging
or withdrew from the study. Within these 105 participants,
100 participants were considered to have normal global
cognition based on their Mini-Mental State Examination
(MMSE; scores can range from 0 to 30, with higher scores
indicating better cognitive function)19 wherein, a cut-off
score <26 was employed to screen out potential dementia
patients. Plasma GFAP concentrations were measured in 96
of the 100 participants, and plasma Aβ1–40 and Aβ1–42
concentrations were measured in 95 of these 100 partici-
pants. However, the total set of GFAP, Aβ1–40, and
Aβ1–42 concentrations were available in 94 of these par-
ticipants. In addition, participants with a Memory Assess-
ment Clinic-Questionnaire (MAC-Q) score of 25–35 were
considered as subjective memory complainers (SMCs, n=
74; a specific form of subjective cognitive decline, defined by
self-reported memory complaints), while those with a
MAC-Q score ≤24 were considered as non-complainers
(n= 22). Details of the participants included within the
current study have been illustrated in Supplementary Fig. 1.
Further, cognitive measures were calculated for verbal
and visual episodic memory, working memory and
executive function, as well as for a global composite score,
that included verbal and visual episodic memory, working
memory and executive function and MMSE scores, for
each participant as described previously20.
All volunteers provided written informed consent prior
to participation, and the Bellberry Human Research Ethics
Committee, Australia (reference number 2012-09-1086)
and the Macquarie University Human Research Ethics
Committee (reference number 5201701078) provided
approval for the study.
Evaluation of neocortical amyloid-β load via PET
All study participants were imaged within 3 months of
blood collection wherein participants underwent Aβ PET
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imaging with 18F-florbetaben (FBB) at Macquarie Medical
Imaging in Sydney, Australia. Participants were adminis-
tered an intravenous bolus of FBB slowly over 30 s, while
in a rested position. Images were acquired over a 20 min
scan, in 5 min acquisitions, beginning 50 min post injec-
tion. Brain Aβ load was calculated, using CapAIBL21, as
the mean standard uptake value ratio (SUVR) of the
neocortical region, including the frontal, superior parietal,
lateral temporal, lateral occipital, and anterior and pos-
terior cingulate regions normalised to the cerebellar cor-
tex. A cut-off score of 1.35 SUVR was used to categorise
participants with low brain Aβ load (Aβ−, SUVR < 1.35)
and high brain Aβ load (Aβ+, SUVR ≥ 1.35)16.
Blood collection, measurement of plasma GFAP, plasma Aβ
and NF-L, and APOE genotyping
All study participants fasted for a minimum of 10 h
overnight prior to blood withdraw employing standard
serological methods and processing16. Following blood
sample processing, plasma fractions were stored at −80 °C
until further testing16. Plasma GFAP concentrations were
measured at Amsterdam University Medical Centers
using the Simoa™ GFAP Discovery Kit on the ultra-
sensitive Single molecule array (Simoa) platform (HDx
instrument) according to the manufacturer’s instructions
(catalogue number 102336, Quanterix, Massachusetts,
USA). Briefly, plasma samples were added into the
aspiration plate of the instrument and diluted four times
using assay diluent. Samples were then incubated simul-
taneously with the capture beads and biotinylated con-
jugate for 35min 15 s followed by a wash step and
incubation of streptavidin-ß-galactosidase (SBG) for
5 min 15 s. Following a next wash step, the beads were
resuspended in a resorufin ß-D-galactopyranoside (RGP)
substrate solution for signal generation. GFAP con-
centrations were calculated using a 4PL 1/Y2 weighted
curve fit on the basis of seven calibrator points (excluding
the blank value) between 1.37 and 1000 pg/mL, according
to the manufacturer’s instructions. The calibrator points
were prepared by serial dilution using a stock of con-
centrated calibrator included in the test kit. Three serum
pools spiked with CSF, to obtain three levels
(high–medium–low), served as QC samples with average
GFAP concentrations of respectively 283.0, 61.0, and
13.6 pg/mL. The repeatability and reproducibility over the
three control samples over the two test runs ranged
respectively between 0–14 (%CV) and 8–16 (%CV).
Plasma Aβ concentrations were measured employing
the Amyblood test that was developed at Amsterdam
University Medical Centers in collaboration with ADx
NeuroSciences (Ghent, Belgium), on the Simoa platform
(HDx instrument, Quanterix), using monoclonal anti-
bodies provided by ADx NeuroSciences22. For Aβ1–40,
C-terminal-specific ADx103 (2G3, Aβx–40) was used as
the capture antibody and N-terminal specific ADx101
(3D6, Aβ1–x) was used as the detector antibody23. For
Aβ1–42, C-terminal-specific ADx102 (21F12, x–42) was
used as the capture antibody and N-terminal-specific
ADx101 (3D6) was used as the detector antibody23.
Briefly, plasma samples were prediluted 20 times for
Aβ1–40 and four times for Aβ1–42 into a 96-well poly-
propylene pre-dilution plate, using assay diluent. Samples
were incubated simultaneously with the capture beads
and biotinylated conjugate for 60min followed by a wash
step and incubation of SBG for 5 min 15 s. Following a
next wash step, the beads were resuspended in a RGP
substrate solution for signal generation. For both Aβ1–40
and Aβ1–42, seven non-blank calibrator points in ready
to use format (in assay diluent) were used between 1 and
20 pg/mL. The analyte concentrations were calculated
using a 4PL non-weighted curve fit. Three non-spiked
individual EDTA plasma samples served as QC samples
for both Aβ1–40 and Aβ1–42 assays, with an average
concentration of respectively 60.7, 112.8, and 74.4 pg/mL
for Aβ1–40, and 16.9, 24.7, and 18.5 pg/mL for Aβ1–42.
The repeatability over the three control samples over all
duplicate values ranged between 0–4 (%CV) and 0–19 (%
CV) for Aβ1–40 and Aβ1–42, respectively. The repro-
ducibility over the two independent test runs ranged
between 3–7 (%CV) and 0–16 (%CV) for Aβ1–40 and
Aβ1–42, respectively.
Plasma NF-L concentrations were also measured
using the Simoa platform, as described previously24,
using two non-competing monoclonal antibodies
wherein capture antibody 47:3 and detector antibody 2:1
were used (Uman Diagnostics, Sweden). Apolipoprotein
E (APOE) genotype was determined from purified
genomic DNA extracted from 0.5 mL whole blood, as
previously described16.
Statistical analyses
Descriptive statistics including means and standard
deviations were calculated for Aβ− and Aβ+ groups, with
comparisons employing Student’s t tests or Chi-square
tests as appropriate. Linear models were employed to
compare continuous variables between Aβ− and Aβ+
groups corrected for covariates age, sex, and APOE ε4
carrier status. Dependent variables were natural log
transformed to better approximate normality and var-
iance homogeneity as required. Spearman’s correlation
coefficient (rs) was employed to investigate correlations
between continuous parameters. Logistic regression with
Aβ−/+ as response was used to evaluate predictive
models and receiver operating characteristic (ROC)
curves constructed from the logistic scores. All analyses
were carried out using IBM® SPSS® Version 23 and ROC
curves were generated using the package Deducer on R
(version 3.2.5).
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Results
Cohort characteristics
Study participant characteristics are presented in Table 1.
No significant differences were observed in sex, age, body
mass index (BMI), MMSE scores, and the number of
SMCs between Aβ− and Aβ+ participants. However, the
APOE ε4 carriage frequency was significantly higher in the
Aβ+ group compared to the Aβ− group, as expected25
(Table 1).
Comparison of plasma GFAP between Aβ− participants
and Aβ+ participants
Plasma GFAP concentrations were significantly higher
in the Aβ+ group (n= 33) compared to the Aβ− group
(n= 63), before and after adjusting for potential risk
factors, age, sex, and APOE ε4 status (Fig. 1 and Table 2,
p < 0.0001).
On stratifying study participants based on subjective
memory complaints (SMC: n= 74 and non-SMC: n= 22),
plasma GFAP continued to remain significantly higher in
the Aβ+ SMCs (n= 25) compared to Aβ− SMCs (n= 49)
before and after adjusting for covariates age, sex, and
APOE ε4 status (Table 2, p < 0.0001). In the non-SMCs,
plasma GFAP was observed to be significantly higher in
Aβ+ non-SMCs (n= 8) compared to the Aβ− non-SMCs
(n= 14) after adjusting for the aforementioned covariates
(Table 2, p < 0.05).
On stratifying study participants by APOE ε4 carriage
(ε4 non-carriers: n= 77 and ε4 carriers: n= 19), sig-
nificantly higher plasma GFAP concentrations were
observed in the Aβ+ group (n= 19) compared to the
Aβ− group (n= 58) within the APOE ε4 non-carriers,
before and after adjusting for potential risk factors, age,
and sex (Supplementary Table 1, p < 0.0001). Within the
APOE ε4 carriers, no significant difference in GFAP
concentration was observed between the Aβ+ group (n=
14) compared to the Aβ− group (n= 5; Supplementary
Table 1). This observation could be attributed to the
modest sample size of the ε4 carrier subset available
within the current study.
Comparison of plasma Aβ1–40, Aβ1–42, and Aβ1–42/
Aβ1–40 ratios between Aβ− participants and Aβ+
participants
Plasma Aβ1–40 and Aβ1–42 concentrations and plasma
Aβ1–42/Aβ1–40 ratios, measured in the study partici-
pants have been presented in Table 3. While no sig-
nificant differences were observed in plasma Aβ1–40
concentrations between the Aβ− (n= 62) and Aβ+
groups (n= 33), significant differences in plasma Aβ1–42
concentrations and Aβ1–42/Aβ1–40 ratios were observed
between the two groups, wherein plasma Aβ1–42 con-
centrations and Aβ1–42/Aβ1–40 ratios were lower in the
Aβ+ group compared to the Aβ− group before and after
correcting for covariates age, sex, and APOE ε4 status
(Fig. 1 and Table 3, p < 0.05).
On stratifying study participants based on subjective
memory complaints (SMC: n= 75 and non-SMC: n= 20),
plasma Aβ1–42 concentrations, and Aβ1–42/Aβ1–40
ratios continued to remain significantly lower in the Aβ+
SMCs (n= 25) compared to Aβ− SMCs (n= 50) before
and after correcting for covariates age, sex, and APOE
ε4 status (Table 3, p < 0.05). However, no significant dif-
ference was observed in plasma Aβ1–42 concentrations,
and Aβ1–42/Aβ1–40 ratios between Aβ+ non-SMCs
(n= 8) and Aβ− non-SMCs (n= 12; Table 3).
On stratifying study participants by APOE ε4 carriage
(ε4 non-carriers: n= 76 and ε4 carriers: n= 19), sig-
nificantly lower plasma Aβ1–42 concentrations and
Aβ1–42/Aβ1–40 ratios were observed in the Aβ+ group
(n= 19) compared to the Aβ− group (n= 57), within the
APOE ε4 non-carrier group, after adjusting for potential
risk factors, age, and sex (Supplementary Table 2, p <
0.05). Within the APOE ε4 carrier group, no significant
differences in plasma Aβ1–42 concentrations and
Aβ1–42/Aβ1–40 ratios were observed between the Aβ+
group (n= 14) compared to the Aβ− group (n= 5; Sup-
plementary Table 2). This observation could be attributed
to the modest sample size of the ε4 carrier subset available
within the current study.
Evaluation of plasma GFAP and Aβ1–42/Aβ1–40 ratios as
predictors of brain Aβ status
Plasma GFAP and Aβ1–42/Aβ1–40 ratios were eval-
uated as potential markers for differentiating between
Aβ+ and Aβ− participants, using logistic regression with
Aβ+ or Aβ− as response. A ‘base’ model incorporating
the major risk factors for AD, namely age, sex, and APOE
Table 1 Cohort characteristics.
Aβ− Aβ+ p
Sex (male/female) 18/45 13/20 0.281
Age (years, mean ± SD) 77.41 ± 5.45 79.64 ± 5.20 0.057
BMI (mean ± SD) 27.28 ± 4.51 27.36 ± 3.79 0.927
APOE ε4 carriers (N (%)) 5 (7.94) 14 (42.42) <0.0001
MMSE (mean ± SD) 28.52 ± 1.16 28.82 ± 1.07 0.230
Subjective memory complainers
(N (%))
49 (77.8) 25 (75.76) 0.823
FBB-PET SUVR (mean ± SD) 1.16 ± 0.09 1.71 ± 0.26 —
Baseline characteristics including sex, age, body mass index (BMI), APOE ε4
status, Mini-mental State Examination (MMSE) scores, subjective memory
complainer status (assessed by the Memory Assessment Clinic-Questionnaire
(MAC-Q) score), and brain Aβ load represented by the standard uptake value
ratio (SUVR) of ligand 18F-florbetaben (FBB) in the neocortical region normalised
with that in the cerebellum, have been compared between Aβ− (SUVR < 1.35, n
= 63) and Aβ+ (SUVR ≥ 1.35, n= 33) study participants. Chi-square tests or
linear models were employed as appropriate.
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Fig. 1 Comparison of plasma GFAP, Aβ1–40, Aβ1–42, and Aβ1–42/Aβ1–40 ratios between Aβ− and Aβ+ cognitively normal older adults.
Plasma GFAP, Aβ1–40 and Aβ1–42 levels, and plasma Aβ1–42/Aβ1–40 ratios were compared between cognitively normal older adults with low brain
Aβ load (Aβ−) and high brain Aβ load (Aβ+) using linear models. Plasma GFAP concentrations were significantly higher, and plasma Aβ1–42/Aβ1–40
ratios were significantly lower in Aβ+ participants compared to Aβ− participants. The line segment within each jitter plot represents the median of
the data and error bars in the graphs represent the interquartile range for the Aβ− and Aβ+ groups. *p < 0.05, **p ≤ 0.001, ***p ≤ 0.0001.
Table 2 Comparison of plasma GFAP between Aβ− and Aβ+ participants.
Aβ− (95% CI) Aβ+ (95% CI) p pa
All participants n= 63 n= 33
151.42 ± 58.49 (129.66–173.18) 240.12 ± 124.88 (210.05–270.18) 7E−6 5.76E−7
SMC n= 49 n= 25
152.73 ± 58.18 (126.35–179.11) 252.22 ± 137.75 (215.29–289.16) b9E−6 4.8E−5
Non-SMC n= 14 n= 8
146.83 ± 61.58 (112.06–181.60) 202.28 ± 63.81 (156.28–248.27) 0.059 0.020
Plasma glial fibrillary acidic protein (GFAP) levels were compared between cognitively normal older adults with low brain Aβ load (Aβ−) and high brain Aβ load (Aβ+)
using linear models. All participants were further categorised into subjective memory complainers (SMC, n= 74) and non-complainers (non-SMC, n= 22). Data are
presented in mean ± SD in pg/mL. p values in bold font were considered as significant (p < 0.05).
ap represents p values adjusted for age, sex, and APOE ε4 status.
bRepresents p values obtained from natural log transformed GFAP concentrations to better approximate normality when required.
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ε4 allele status was generated, and was observed to have
an area under the ROC curve (AUC (confidence interval,
CI)) of 0.782 (CI= 0.684–0.880) and was outperformed by
GFAP alone (AUC= 0.795, CI= 0.703–0.888, sensitivity=
73%, specificity= 72%, p(GFAP)= 0.0001), base+GFAP
(AUC= 0.906, CI= 0.849–0.964, sensitivity= 85%, spe-
cificity= 80%, p(GFAP)= 0.00006), base+Aβ1–42/
Aβ1–40 ratio (AUC= 0.842, CI= 0.758–0.926, sensitiv-
ity= 85%, specificity= 74%, p(Aβ42/Aβ40 ratio)= 0.013),
and base+GFAP+Aβ1–42/Aβ1–40 ratio (AUC= 0.919,
CI= 0.867–0.972, sensitivity= 91%, specificity= 80%,
p(GFAP)= 0.0001, p(Aβ1–42/Aβ1–40 ratio)= 0.042) in
distinguishing Aβ+ from Aβ− participants (Fig. 2).
Association of plasma GFAP with AD risk factors, cognitive
measures, and neurodegeneration blood marker, NF-L, in
all participants
Plasma GFAP levels correlated with age (rs= 0.342, p=
0.001), however, no significant association was observed
with sex (mean ± SD (pg/mL): males= 160.22 ± 50.89;
females= 192.25 ± 110.56; p= 0.128) and APOE ε4 allele
carriage (mean ± SD (pg/mL): non-carriers= 181.98 ±
102.44; carriers= 181.62 ± 68.31; p= 0.988). Plasma
GFAP was observed to have a significant inverse corre-
lation with working memory and executive function (rs=
−0.230, p= 0.024), but not with verbal, visual, and epi-
sodic memory (rs=−0.131, p= 0.204), while an inverse
trend towards statistical significance was observed for the
global composite score (rs=−0.185, p= 0.072). Plasma
GFAP levels were not observed to be significantly
different between SMCs and non-SMCs (mean ± SD
(pg/mL): non-SMC= 167 ± 66.71; SMC= 186.34 ±
103.48; p= 0.411). Plasma GFAP was also observed to
correlate with plasma NF-L (rs= 0.441, p= 7E−7).
Discussion
Findings from the current study show that plasma
GFAP levels are increased in cognitively normal older
adults with high brain Aβ load, indicating that elevated
plasma GFAP may serve as an early blood-based bio-
marker to identify individuals at risk of AD, prior to the
manifestation of clinical symptoms. Our observations
build on previous reports of elevated plasma GFAP levels
in symptomatic early-onset AD and late-onset AD7,8.
Further, observations from our study also show that
GFAP along with the common AD risk factors (age, sex,
and APOE ε4 carriage), and plasma Aβ1–42/Aβ1–40 ratio
(a blood-based biomarker associated with brain Aβ sta-
tus13,15) distinguished between Aβ− and Aβ+ individuals
with 90% sensitivity and 80% specificity, wherein GFAP
and plasma Aβ1–42/Aβ1–40 ratio were statistically sig-
nificant additional predictors of brain Aβ load status, over
and above the base model.
GFAP is one of the main intermediate filament proteins
in astrocytes that has been thought to be involved in (i)
fundamental cellular processes, such as cellular moti-
lity26,27, proliferation28,29, and vesicle trafficking30, (ii)
interactions between astrocytes and neurons31–33, (iii)
maintenance of the integrity of the blood–brain barrier
and central nervous system myelination34,35, and (iv)
Table 3 Comparison of plasma Aβ1–40, Aβ1–42, and Aβ1–42/Aβ1–40 ratios between Aβ− and Aβ+ participants.
Aβ− (95% CI) Aβ+ (95% CI) p pa
All participants n= 62 n= 33
Aβ1–40 95.19 ± 14.78 (91.27–99.10) 98.37 ± 16.88 (93.00–103.74) 0.344 0.659
Aβ1–42 21.96 ± 4.58 (20.70–23.22) 19.54 ± 5.74 (17.81–21.27) 0.027 0.022
Aβ1–42/Aβ1–40 ratio 0.232 ± 0.042 (0.221–0.243) 0.200 ± 0.050 (0.184–0.215) 0.001 0.004
SMC n= 50 n= 25
Aβ1–40 95.62 ± 14.74 (91.19–100.05) 98.67 ± 17.54 (92.41–104.94) 0.430 0.624
Aβ1–42 22.05 ± 4.69 (20.58–23.52) 19.12 ± 6.17 (17.02–21.19) 0.024 0.015
Aβ1–42/Aβ1–40 ratio 0.232 ± 0.044 (0.218–0.245) 0.195 ± 0.056 (0.176–0.214) 0.003 0.003
Non-SMC n= 12 n= 8
Aβ1–40 93.39 ± 15.48 (83.96–102.83) 97.41 ± 15.68 (85.86–108.97) 0.578 0.093
Aβ1–42 21.57 ± 4.26 (19.02–24.12) 20.89 ± 4.11 (17.77–24.01) 0.727 0.634
Aβ1–42/Aβ1–40 ratio 0.232 ± 0.039 (0.213–0.252) 0.214 ± 0.017 (0.190–0.238) 0.230 0.244
Plasma Aβ1–40 and Aβ1–42 concentrations measured using the Amyblood test (ADx Neurosciences), and their ratio (Aβ1–42/Aβ1–40) were compared between
cognitively normal individuals with low brain Aβ load (Aβ−) and high brain Aβ load (Aβ+) using linear models. All participants were further categorised into
subjective memory complainers (SMC, n= 75) and non-SMC (n= 20). Data are presented in mean ± SD in pg/mL. p values in bold font were considered significant
(p < 0.05).
ap represents p values adjusted for age, sex, and APOE ε4 status.
Chatterjee et al. Translational Psychiatry           (2021) 11:27 Page 6 of 10
protection after neuronal injury36,37. It could be posited
that the elevated plasma GFAP levels observed in the
Aβ+ individuals within the current study are attributed
to a compromised blood–brain barrier along with an
upregulation of GFAP, following astrogliosis, resulting
in higher blood GFAP levels in Aβ+ individuals.
Findings from the current study are consistent with
previous reports of higher GFAP expression in AD
brain tissue38, and the association between Aβ plaques
and a neuroinflammatory response, with astroglial
activation and increased GFAP expression5,39–42. Fur-
thermore, in line with our findings, PET studies using
tracer 11C-deuterium-L-deprenyl (used for visualisation
of activated astrocytes) also suggest that reactive
astrocytosis is potentially a prodromal feature in AD
development4,43,44.
Fig. 2 Receiver operating characteristic curves for the prediction of Aβ+ versus Aβ− participants. Receiver operating characteristic (ROC)
curves are presented for A the ‘base’ model (BM) comprising major risk factors age, sex, and APOE ε4 allele status (CI= 0.684–0.880), B plasma GFAP
(CI= 0.703–0.888), C plasma Aβ1–42/Aβ1–40 ratio (CI= 0.563–0.785), D BM+ GFAP (CI= 0.849–0.964), E BM+ plasma Aβ1–42/Aβ1–40 ratio (CI=
0.758–0.926), and F BM+ GFAP+ plasma Aβ1–42/Aβ1–40 ratio (CI= 0.867–0.972). The base model was outperformed by models B, D–F. Logistic
regression models were employed to perform the analyses. Data from 94 participants were utilised for the analyses (Aβ−, n= 61; Aβ+, n= 33). GFAP
glial fibrillary acidic protein, AUC area under the curve, CI confidence interval.
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Interestingly, within the current study, plasma GFAP
was observed to be significantly higher in the Aβ+ group
(compared to the Aβ− group), in both SMCs and non-
SMCs after adjusting for potential confounding variables,
although the significance level observed in SMCs was to a
much greater extent compared to that observed in the
non-SMCs. However, plasma Aβ1–42/Aβ1–40 ratios
were only significantly lower in Aβ+ participants (com-
pared to the Aβ− participants) within the SMC subset,
after stratifying participants based on their SMC status.
This observation is consistent with a previous study
employing the same cohort using a different Aβ mea-
surement assay13.
In addition, the current study also stratified participants
based on APOE ε4 allele carriage and observed that while
GFAP was significantly higher in the Aβ+ APOE ε4 non-
carriers (compared to the Aβ− APOE ε4 non-carriers), and
Aβ1–42/Aβ1–40 ratios were significantly lower in the Aβ+
APOE ε4 non-carriers (compared to the Aβ− APOE ε4
non-carriers), plasma GFAP levels, and Aβ1–42/Aβ1–40
ratios were not significantly altered in Aβ+ versus Aβ−
APOE ε4 carriers. This observation could be attributed to
the modest sample size of the ε4 carrier subset available
within the current study. Nonetheless, the observations of
plasma GFAP and Aβ1–42/Aβ1–40 ratios remaining sig-
nificantly altered between Aβ− and Aβ+ participants
within the APOE ε4 non-carrier subset from this explora-
tory analysis may be viewed as a beneficial feature for early
AD biomarkers, given that the presence of the APOE ε4
allele in itself is a major risk factor for the disease.
Within the current study, we observed a correlation
between plasma GFAP and age, consistent with a previous
report8. Increased GFAP expression with age has also
been reported in the brain45,46, caused by increased GFAP
transcription, which has been suggested to be caused due
to increased oxidatively damaged protein during ageing47.
In addition, within the current study, plasma GFAP
inversely correlated with cognitive performance, particu-
larly with working memory and executive function;
however, further studies are required to validate these
observations.
Interestingly, we observed a highly significant correlation
between plasma GFAP and plasma NF-L (comparison of
plasma NF-L levels between Aβ− and Aβ+ participants
are presented in Supplementary Table 3). This correlation
observed between plasma GFAP and plasma NF-L,
revealing the association between astrocytic damage and
axonal damage, is consistent with previous reports48,49.
In addition, the presence GFAP-IgG seropositivity in
autoimmune GFAP astrocytopathy, an autoimmune dis-
ease of the nervous system50 and the increased risk of AD
in individuals with autoimmune diseases51, along with our
observations of increased plasma GFAP in individuals at
risk of AD, warrant further investigation into the link
between AD and autoimmune disorders, and the inves-
tigation of possible mechanisms associated with this link.
It is acknowledged that the current study has limita-
tions, given its modest sample size and cross-sectional
design, particularly after stratifying the cohort into SMC
and non-SMC subsets or APOE ε4 non-carrier and carrier
subsets. Therefore, further studies are required to validate
the current findings in larger independent cohorts, using
both cross-sectional and longitudinal study designs.
Longitudinal studies will provide more insight into the
trajectory of plasma GFAP alterations associated with the
progression of AD pathogenesis. In addition, since
increased plasma GFAP has been reported to be asso-
ciated with other dementias8 and neurodegenerative dis-
orders49,52, the specificity of GFAP as a biomarker to
identify cognitively normal older adults at risk of AD
warrants further research. However, it must also be noted
that while GFAP may be associated with other dementias
and neurodegenerative disorders, our data clearly show a
significant positive association between GFAP and brain
Aβ load measured by PET (Supplementary Fig. 2), a gold
standard biomarker for AD.
To conclude, the current study is the first to demonstrate
increased plasma GFAP levels in cognitively normal older
adults at risk of AD. These observations suggest that
astrocytic damage begins from the pre-symptomatic stage
of AD and is associated with brain Aβ load. Further,
observations from the current study show that the combi-
nation of plasma GFAP and plasma Aβ1–42/Aβ1–40 ratios
along with the major AD risk factors, have the potential to
differentiate between Aβ+ and Aβ− individuals, albeit
further studies in independent cohorts are required to
validate these findings. The utilisation of plasma GFAP to
identify individuals at risk of AD (Aβ+ individuals), decades
before the onset of AD clinical symptoms for clinical trials
could assist with reducing the considerable screening costs,
thereby facilitating much needed prevention programmes
and clinical intervention trials.
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